POAI - Predictive Oncology acquires zPREDICTA

Predictive Oncology (NASDAQ:POAI) has acquired of zPREDICTA, a company pioneering tumor-specific in vitro 3D cell culture models for drug discovery and development. The acquisition adds a new anticipated revenue stream to Predictive Oncology. Based on zPREDICTA's historical operating results and anticipated synergies, Predictive Oncology believes the acquisition will be accretive on a short term as well as a long term basis. zPREDICTA’s technology coupled with Predictive Oncology’s unique database and machine learning algorithms CoRE and PeDAL will make more accurate predictions of treatment outcomes. "The acquisition of zPREDICTA adds an established company with clear synergies to Predictive Oncology's team, not to mention a progressive revenue stream. zPREDICTA's work in the development of new 3D cell culture methods gives us yet another competitive advantage in helping identify, develop, and expedite new cancer therapies," says J. Melville Engle, CEO and Chairman of Predictive Oncology.  Shares are up 3.9% PM.

For further details see:

Predictive Oncology acquires zPREDICTA